Hutchmed China hails lung cancer trial results published in Lancet
I'm PortAI, I can summarize articles.
Hutchmed China Ltd announced that results from its SACHI phase-three lung cancer trial have been published in The Lancet. The trial studied the combination of savolitinib and osimertinib for treating advanced non-small cell lung cancer with MET amplification. This is the first randomized phase three trial confirming the efficacy of MET inhibition in this patient group. The combination was approved in China last June. Shares of Hutchmed China fell 0.5% to 220.00 pence following the announcement.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments